What does De Scheerder Pharmaceuticals do?

De Scheerder Pharmaceuticals is filed with the CBE under the catch-all “Overige zakelijke dienstverlening”, a code that says little about what the company actually does. Private Limited, started on 13 August 2020, 1 establishment.

What is the address of De Scheerder Pharmaceuticals?

The registered office of De Scheerder Pharmaceuticals is located at Mariakerkegeest 12, 9030 Gent.

Is De Scheerder Pharmaceuticals still active?

Yes. According to the CBE (31 October 2026) De Scheerder Pharmaceuticals is active, legal situation “Normale toestand”, started on 13 August 2020.

Is De Scheerder Pharmaceuticals registered on Peppol?

Yes, De Scheerder Pharmaceuticals is registered on the Peppol network with ID 0208:0752564602.

What is the enterprise number of De Scheerder Pharmaceuticals?

The enterprise number of De Scheerder Pharmaceuticals is BE0752564602.

When was De Scheerder Pharmaceuticals founded?

De Scheerder Pharmaceuticals was founded on 13 August 2020.

Who are the directors of De Scheerder Pharmaceuticals?

According to the 2025 annual accounts, the directors of De Scheerder Pharmaceuticals are: Valerie De Scheerder.

Is De Scheerder Pharmaceuticals a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 13 August 2020; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did De Scheerder Pharmaceuticals make in 2025?

De Scheerder Pharmaceuticals posted a profit after taxes of € 25,124 in financial year 2025.

What is the revenue of De Scheerder Pharmaceuticals?

As a small company, De Scheerder Pharmaceuticals is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 33,076.

De Scheerder Pharmaceuticals (Private Limited) - Gent

Dossier De Scheerder Pharmaceuticals, printed on 1 November 2026 from databakkes.be/en/0752564602/de-scheerder-pharmaceuticals. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

De Scheerder Pharmaceuticals from Gent, company number BE0752564602, closed financial year 2025 with a result of € 25,124 after tax. For that financial year De Scheerder Pharmaceuticals recorded a gross margin of € 33,076 and equity of € 68,424. Compared with financial year 2024, the result moved from € 13,680 to € 25,124. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on January 17, 2026.

What it is worth Growing

€ 68,424

▲ 52% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 25,124

▲ 84% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 60,607

▲ 56% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 1,718 paid out

7 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 2,014

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 1,469

▲ 16% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 24

▼ 98% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 6,068 Gross margin 2022: € 6,068 First fiscal year in the series	€ 30,363 Gross margin 2023: € 30,363 ▲ € 24,296 vs 2022 (€ 6,068) Favourable step	€ 18,416 Gross margin 2024: € 18,416 ▼ 39% vs 2023 (€ 30,363) Unfavourable step	€ 33,076 Gross margin 2025: € 33,076 ▲ 80% vs 2024 (€ 18,416) Favourable step	▲ 80%
Profit after taxes	€ 3,891 Profit after taxes 2022: € 3,891 First fiscal year in the series	€ 23,354 Profit after taxes 2023: € 23,354 ▲ € 19,463 vs 2022 (€ 3,891) Favourable step	€ 13,680 Profit after taxes 2024: € 13,680 ▼ 41% vs 2023 (€ 23,354) Unfavourable step	€ 25,124 Profit after taxes 2025: € 25,124 ▲ 84% vs 2024 (€ 13,680) Favourable step	▲ 84%
Equity	€ 11,251 Equity 2022: € 11,251 First fiscal year in the series	€ 33,005 Equity 2023: € 33,005 ▲ 193% vs 2022 (€ 11,251) Favourable step	€ 45,019 Equity 2024: € 45,019 ▲ 36% vs 2023 (€ 33,005) Favourable step	€ 68,424 Equity 2025: € 68,424 ▲ 52% vs 2024 (€ 45,019) Favourable step	▲ 52%
Total debts	€ 4,138 Total debts 2022: € 4,138 First fiscal year in the series	€ 3,825 Total debts 2023: € 3,825 ▼ 8% vs 2022 (€ 4,138) Favourable step	€ 4,369 Total debts 2024: € 4,369 ▲ 14% vs 2023 (€ 3,825) Unfavourable step	€ 3,278 Total debts 2025: € 3,278 ▼ 25% vs 2024 (€ 4,369) Favourable step	▼ 25%
Cash	€ 6,597 Cash 2022: € 6,597 First fiscal year in the series	€ 25,389 Cash 2023: € 25,389 ▲ 285% vs 2022 (€ 6,597) Favourable step	€ 38,743 Cash 2024: € 38,743 ▲ 53% vs 2023 (€ 25,389) Favourable step	€ 60,607 Cash 2025: € 60,607 ▲ 56% vs 2024 (€ 38,743) Favourable step	▲ 56%
Retained profit	€ 6,251 Retained profit 2022: € 6,251 First fiscal year in the series	€ 28,005 Retained profit 2023: € 28,005 ▲ € 21,754 vs 2022 (€ 6,251) Favourable step	€ 40,019 Retained profit 2024: € 40,019 ▲ 43% vs 2023 (€ 28,005) Favourable step	€ 63,424 Retained profit 2025: € 63,424 ▲ 58% vs 2024 (€ 40,019) Favourable step	▲ 58%
Dividend	€ 800 Dividend 2022: € 800 First fiscal year in the series	€ 1,600 Dividend 2023: € 1,600 ▲ 100% vs 2022 (€ 800) Unchanged	€ 1,666 Dividend 2024: € 1,666 ▲ 4% vs 2023 (€ 1,600) Unchanged	€ 1,718 Dividend 2025: € 1,718 ▲ 3% vs 2024 (€ 1,666) Unchanged	▲ 3%
Balance sheet total	€ 15,389 Balance sheet total 2022: € 15,389 First fiscal year in the series	€ 36,830 Balance sheet total 2023: € 36,830 ▲ 139% vs 2022 (€ 15,389) Unchanged	€ 49,387 Balance sheet total 2024: € 49,387 ▲ 34% vs 2023 (€ 36,830) Unchanged	€ 71,702 Balance sheet total 2025: € 71,702 ▲ 45% vs 2024 (€ 49,387) Unchanged	▲ 45%

Key figures of De Scheerder Pharmaceuticals, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.

What happened to De Scheerder Pharmaceuticals?

What happened at De Scheerder Pharmaceuticals in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jan 17, 2026 New annual accounts for financial year 2025: profit of € 25,124 (▲ 84% vs 2024). Source: NBB ↗
Aug 13, 2020 New establishment in Gent. KBO
2020 Valerie De Scheerder became a director. NBB
Aug 13, 2020 Start of the company according to the CBE. KBO

In short

From € 3,891 profit in 2022 to € 25,124 profit in 2025.

Paid € 18,243 in corporate taxes since 2022.

Best year ever: 2025, with € 25,124 profit.

Paid out € 5,784 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Valerie De Scheerder

De Scheerder Pharmaceuticals

Behind De Scheerder Pharmaceuticals is Valerie De Scheerder.

Directors

According to the 2025 annual accounts

Valerie De Scheerder

Director

since 2020

Establishments

Establishment units

Physical locations of this company

Registered office

Mariakerkegeest 12

9030 Gent

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0752.564.602
VAT number: BE 0752.564.602
Registered office: Mariakerkegeest 12, 9030 Gent
Names & denominations: De Scheerder Pharmaceuticals
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 13 August 2020
Peppol: Active · Active since 27 Feb 2025
Activities · NACE: Overige zakelijke dienstverlening, neg

View on CBE Public ↗ Annual accounts (NBB) ↗